Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Efpeglenatide

Stage Phase 3Stale

Sponsor Sanofi

Route oral and injection

Sources

registry, as of 2021-10-15Stale

https://clinicaltrials.gov/study/NCT03770728

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 312. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone or in combination with sul

ClinicalTrials.gov NCT03770728 protocol and results modules

registry, as of 2021-11-01Stale

https://clinicaltrials.gov/study/NCT03684642

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 908. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin

ClinicalTrials.gov NCT03684642 protocol and results modules

registry, as of 2022-01-18Stale

https://clinicaltrials.gov/study/NCT03353350

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hanmi Pharmaceutical Company Limited. Enrollment 406. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives:

ClinicalTrials.gov NCT03353350 protocol and results modules

registry, as of 2021-12-02Stale

https://clinicaltrials.gov/study/NCT03713684

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s). Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 370. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with basal insulin alone or in combination with

ClinicalTrials.gov NCT03713684 protocol and results modules

registry, as of 2021-10-15Stale

https://clinicaltrials.gov/study/NCT03496298

Effect of Efpeglenatide on Cardiovascular Outcomes. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 4076. Conditions Type 2 Diabetes Mellitus. Primary Objective: To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high cardiovascular (CV) risk. Secondary Objectives: To demonstrate that efpeglenatide 4

ClinicalTrials.gov NCT03496298 protocol and results modules

Studies

AMPLITUDE-S

Registry NCT03770728

Phase Phase 3

Status Terminated

Enrollment 312

Start 2019-08-01

Primary completion 2020-11-28

Study completion 2020-12-27

Placebo

Regimen once weekly

Weeks 30

Population Type 2 Diabetes Mellitus

Efpeglenatide 2 mg

Dose 2 mg

Regimen once weekly

Weeks 30

Comparator placebo

Population Type 2 Diabetes Mellitus

Efpeglenatide 4 mg

Dose 4 mg

Regimen once weekly

Weeks 30

Comparator placebo

Population Type 2 Diabetes Mellitus

Efpeglenatide 6 mg

Dose 6 mg

Regimen once weekly

Weeks 30

Comparator placebo

Population Type 2 Diabetes Mellitus

AMPLITUDE-D

Registry NCT03684642

EudraCT 2017-002956-10

Phase Phase 3

Status Terminated

Enrollment 908

Start 2018-09-26

Primary completion 2020-10-13

Study completion 2020-11-17

Efpeglenatide 4 mg

Dose 4 mg

Regimen once weekly

Weeks 56

Population Type 2 Diabetes Mellitus

Efpeglenatide 6 mg

Dose 6 mg

Regimen once weekly

Weeks 56

Population Type 2 Diabetes Mellitus

Dulaglutide 1.5 mg

Dose 1.5 mg

Regimen once weekly

Weeks 56

Population Type 2 Diabetes Mellitus

AMPLITUDE-M

Registry NCT03353350

Phase Phase 3

Status Completed

Enrollment 406

Start 2017-12-05

Primary completion 2020-01-29

Study completion 2020-09-07

Efpeglenatide 2mg

Dose 2mg

Regimen once weekly

Weeks 56

Comparator placebo

Population Type 2 Diabetes Mellitus

Efpeglenatide 4 mg

Dose 4 mg

Regimen once weekly

Weeks 56

Comparator placebo

Population Type 2 Diabetes Mellitus

Efpeglenatide 6 mg

Dose 6 mg

Regimen once weekly

Weeks 56

Comparator placebo

Population Type 2 Diabetes Mellitus

Placebo

Regimen once weekly

Weeks 56

Population Type 2 Diabetes Mellitus

AMPLITUDE-L

Registry NCT03713684

Phase Phase 3

Status Terminated

Enrollment 370

Start 2018-11-09

Primary completion 2020-11-20

Study completion 2021-01-04

Placebo

Regimen once weekly

Weeks 56

Population Type 2 Diabetes Mellitus

Efpeglenatide 2 mg

Dose 2 mg

Regimen once weekly

Weeks 56

Comparator placebo

Population Type 2 Diabetes Mellitus

Efpeglenatide 4 mg

Dose 4 mg

Regimen once weekly

Weeks 56

Comparator placebo

Population Type 2 Diabetes Mellitus

Efpeglenatide 6 mg

Dose 6 mg

Regimen once weekly

Weeks 56

Comparator placebo

Population Type 2 Diabetes Mellitus

AMPLITUDE-O

Registry NCT03496298

EudraCT 2017-002954-35

Phase Phase 3

Status Terminated

Enrollment 4076

Start 2018-04-27

Primary completion 2020-12-10

Study completion 2020-12-10

Placebo

Regimen once weekly

Weeks 4

Population Type 2 Diabetes Mellitus

Efpeglenatide 4 mg

Dose 4 mg

Regimen once weekly

Weeks 4

Comparator placebo

Population Type 2 Diabetes Mellitus

Efpeglenatide 6 mg

Dose 6 mg

Regimen once weekly

Weeks 4

Comparator placebo

Population Type 2 Diabetes Mellitus